Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc > CLAS

<< Previous

Bullboard Posts

Next >>

Comment by PTBaileyon Jul 14, 2021 9:41am

150 Views

Post# 33541673

RE:CLAS

mavericks2020 wrote: Investors are shifting their correction investment strategies alongside market selloffs at large. A significant part of this strategy is to stay safe, calm, and diversified, but another key factor for many investors on the Stockhouse Bullboards is to gauge which companies will be able to recover, and when.

This week, we highlight two sides of the impact the markets have faced so far, by looking at the most-viewed companies in resources, as well as healthcare, specifically cannabis.

Starting with a look at what is happening in cannabis and the companies operating in and around that market, Kalytera Therapeutics Inc. (TSX-V:KLY, Forum) is now going by the name Claritas Pharmaceuticals, Inc. and this week, the CBD biotech company touted the potential of its proprietary nitric oxide releasing compound, R-107, as a therapy for coronavirus and COVID-19 infection, citing new data by Massachusetts General Hospital. Claritas has concentrated its focus on the development on R-107. The nitric oxide-releasing compound. Following administration orally in a capsule, or by nasal spray, or by injection, R-107 enters the bloodstream, where it slowly releases nitric oxide systemically over 24 hours.